|
Daiichi, ArQule End Phase III Drug Combo Trial
Daiichi Sankyo and ArQule are discontinuing a Phase III trial of tivantinib in combination with erlotinib for patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC).
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives